Clinique Laflamme Wins the 2025 Consumer Choice Award
MONTRÉAL, QC / ACCESS Newswire The Consumer Choice Award (CCA) is proud to name Clinique Laflamme as the top medical aesthetic clinic in the Greater Montreal area.
This prestigious recognition highlights the excellence of an establishment at the intersection of science, cutting-edge technology, and the art of personalized beauty.
Since its founding in 2010, Clinique Laflamme has established itself as a leading authority in medical aesthetics in Quebec. Its mission is clear: to place medicine at the service of natural, lasting beauty, while respecting overall well-being, through a personalized approach and the integration of next-generation technologies. At the heart of this vision is Dr. Nathalie Laflamme, a physician recognized in aesthetic medicine by the Collège des médecins du Québec. Certified by the European College of Aesthetic Medicine & Surgery (ECAMS), she is a leading expert in advanced aesthetic injectables and tissue biostimulation, offering holistic and harmonious rejuvenation with natural results and customized care.
Creator of the exclusive Lift Laflamme© protocol, she embodies a new generation of aesthetic physicians combining technical mastery with artistic vision.
Driven by a constant desire to refine her practice, Dr. Laflamme has expanded her expertise through advanced training in Europe, the United States, and Canada. This ongoing commitment to education allows her to remain at the forefront of the most effective, innovative, and safest medical advancements in the field.
Clinique Laflamme offers a full range of high-end medical-aesthetic treatments, including:
Next generation injectables: neuromodulators and tailored fillers to smooth wrinkles, sculpt volume, and enhance features with finesse.
Laser and light-based technologies: for pigmentation correction, skin tightening, collagen stimulation, and precision hair removal.
Non-invasive body contouring: advanced technology solutions designed to sculpt the body without surgery or downtime.
Medical-grade skincare: personalized treatments that promote luminous, even, and resilient skin.
Tissue biostimulation: a revolutionary breakthrough that reactivates the skin's natural regenerative power, from face to body, for a tightening effect and deep revitalization – all without invasive procedures.
'This award reflects our commitment to delivering ethical, science-based, and personalized aesthetic care. We believe in an evolving beauty – one that is supported by medical intelligence, technological precision, and a deep understanding of our patients,' says Dr. Laflamme.
'We are deeply grateful to our patients for their continued trust. It is an honour we carry with pride and responsibility.'
Guided by a culture of excellence, Clinique Laflamme stands as a leader in modern aesthetic medicine. Visionary, refined, and deeply human, it remains the destination of choice for those seeking personalized care, elegant results, and a safe, cutting-edge approach to beauty and well-being.
To learn more about Clinique Laflamme, CLICK HERE or visit www.cliniquelaflamme.com.
About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.
Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com
SOURCE: Consumer Choice Award
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
20 hours ago
- Miami Herald
Retransmission - Dr. Meegan Gruber Shares Insight on Plastic Surgery Transparency: How Younger Generations Are Shaping a New Era of Body Authenticity
A culture change is affecting how people talk about cosmetic surgery, from popular TikToks to BBL reversals. Dr. Meegan Gruber shows why choices made with knowledge and power are becoming more critical. TAMPA, FLORIDA / ACCESS Newswire / June 20, 2025 / Younger people are driving a new wave of openness in the world of cosmetic surgery. They are not only accepting procedures but also expecting complete transparency about them. The way people talk about plastic surgery is changing. Body-positive creators are sharing their stories online, and an increasing number of influencers are discussing their personal transformations and life changes. Gruber Plastic Surgery is at the forefront of this culture change. Board-certified plastic surgeon and founder of Gruber Plastic Surgery, Dr. Meegan Gruber MD PhD, notes that more patients are coming in with greater knowledge, asking more in-depth questions, and selecting procedures that align with a growing movement toward natural beauty and authenticity. "People don't feel like they have to hide their procedures anymore," says Dr. Gruber. "Patients want to be real, and not just in how they look. They also want to know that their choices are respected and supported." "They want to know if the changes can be undone, if the results will still work in the future, and how their bodies will change." This change has also led to the so-called BBL Reversal Era, in which many people are seeking more natural, proportional results after years of trying to achieve curves that were too large. Instead of making surgery look cool, today's patients are pushing for adults to make decisions based on self-awareness and sustainability. This is reflected in the popularity of awake procedures, such as awake liposuction, at Gruber Plastic Surgery. During these procedures, patients remain awake and aware throughout, and they are actively involved in the conversation during the surgery. This method not only speeds up recovery but also fosters trust and openness, which are traits that today's patients consider essential. Dr. Gruber says, "Education is a form of empowerment." "Whether someone is thinking about a first procedure or a revision, we want to take the mystery out of every step." There is no such thing as a small question. We don't see radical openness as a trend; it's our way of life. It's less of a secret to have cosmetic surgery now that TikTok, Reddit forums, and wellness shows talk about everything from how to care for scars to the different kinds of implants. As a result? A public that knows more has fewer unrealistic demands and cares more about safety and ethics. Suppose you're thinking about getting surgery, like a breast revision, liposuction, or a BBL reversal. In that case, Dr. Gruber advises that you should undergo a comprehensive evaluation and prioritize your own goals over what others think is cool. About Gruber Plastic Surgery Gruber Plastic Surgery, located in Tampa, FL, is led by Dr. Meegan Gruber, MD Ph.D., a board-certified plastic surgeon renowned for her pioneering work in awake surgery. Dr. Gruber, also the star of "Awake Surgery," which you can stream today on TLC GO, HBO MAX, Hulu, Discovery+, and other streaming platforms, integrates advanced techniques and cutting-edge technology to deliver safe, comfortable, and natural-looking results with minimized recovery time. Specializing in awake surgeries, the clinic offers a range of state-of-the-art procedures. Dr. Gruber is committed to innovation and education, ensuring precision and safety in every treatment, while enhancing patient confidence through individualized care and surgical expertise. Contact Information Madeleine Moench madeleinem@ Related Images
Miami Herald
a day ago
- Miami Herald
Dr. Todd H. Lanman to Present at International Total Disc Arthroplasty Masterclass in Amsterdam
BEVERLY HILLS, CA / ACCESS Newswire / June 18, 2025 / World-renowned spinal neurosurgeon and motion preservation expert Dr. Todd H. Lanman will join an elite international faculty at the Total Disc Arthroplasty Masterclass in Amsterdam on June 20, 2025. Dr. Lanman will deliver a series of educational presentations and case-based discussions on the expanding indications for total disc replacement (TDR)-including highly complex cases. Dr. Lanman, founder of Lanman Spinal Neurosurgery and ADR Spine, will present on challenging lumbar and cervical disc arthroplasty cases, including those involving multilevel degeneration, prior fusions, or advanced pathology. His contributions will spotlight evolving strategies that broaden candidacy for motion-preserving surgery-particularly for patients once limited to spinal fusion. He will also participate in a faculty-led panel discussing revision strategies and clinical decision-making in difficult and multi-level cases. "We are forging the new age of spinal surgery," said Dr. Lanman. "With the right technology and expertise, we can now offer motion-preserving solutions to patients who were never considered candidates for disc replacement-patients with prior fusions, complex anatomies, or multilevel disease." The Masterclass begins on June 19, 2025, with a dinner and pre-conference case discussions, followed by a full day of expert-led lectures and panels on June 20 at the nhow Amsterdam RAI Hotel. Dr. Todd Lanman will join a distinguished international faculty that includes Dr. Scott Blumenthal (Texas Back Institute), Prof. Dr. Rudolf Bertagnoli (Pro-Spine ECSA, Germany), Dr. Thierry Marnay (CCV Montpellier, France), and Prof. Matthew Scott-Young (Gold Coast Spine, Australia). Dr. Thierry Marnay will deliver a keynote lecture entitled "What Gives? Why are Spine Surgeons So Far Behind Total Joint Surgeons?" addressing systemic, cultural, and clinical barriers to wider adoption of disc arthroplasty. He will also co-lead participant case discussions, contribute to the session on advanced lumbar case reviews, and serve on the expert faculty panel for complex cervical case analysis Prof. Matthew Scott-Young will open the Masterclass with a program overview and contribute to case discussions throughout the event. His formal lectures will address cervical disc indications, including motion preservation versus ACDF, and provide an in-depth analysis of cervical disc designs, covering implant materials, mechanical philosophy, and evolving technologies such as fixed versus mobile cores. Prof. Dr. Rudolf Bertagnoli will present on lumbar complications and revision surgery strategies, including case examples highlighting surgical decision-making in complex revision scenarios. He will also lead sessions on optimizing surgical technique for multilevel cervical arthroplasty and challenging anatomy and participate in interactive discussions on complex cervical cases and disc selection considerations by spinal level. Dr. Scott Blumenthal will deliver a foundational lecture on lumbar disc arthroplasty, focusing on indications, patient selection, and clinical evidence, as well as considerations for when fusion may still be relevant. He will also lead case discussions on lumbar pathology, and present strategies for cervical revision surgery and participate in the final panel addressing the future of disc arthroplasty. The Masterclass underscores a growing international consensus that spinal fusion should no longer be the default solution for degenerative disc disease and that total disc arthroplasty is both viable and preferable in an expanding range of cases. About Dr. Todd H. Lanman Dr. Todd H. Lanman is a globally recognized spinal neurosurgeon, thought leader, and innovator in motion-preserving spine surgery. With over three decades of clinical experience and more than 25 years in practice in Beverly Hills, he is the founder of Lanman Spinal Neurosurgery and ADR Spine. Dr. Lanman has pioneered numerous surgical firsts in artificial disc replacement (ADR), multilevel arthroplasty, and fusion reversal. He is also a lecturer, educator, and contributor to peer-reviewed publications, advancing the field of spine surgery both academically and in practice. About Lanman Spinal Neurosurgery Lanman Spinal Neurosurgery is a leading center for advanced spine care specializing in artificial disc replacement, fusion reversal, and motion preservation. With a focus on restoring full function and range of motion, the practice has been at the forefront of spine health innovation for over 25 years. About ADR Spine ADR Spine is a national leader in motion-preserving spinal care, dedicated to advancing the science and practice of artificial disc replacement. Founded by Dr. Todd H. Lanman, ADR Spine is a trusted platform connecting patients with top spine arthroplasty specialists. Through its Top Doctors in Arthroplasty program, ADR Spine rigorously evaluates surgeons based on outcomes, success rates, and clinical expertise. Learn more at CONTACT: Brandi KamenarBrandi Kamenar Brand Management310-734-6180 SOURCE: Lanman Spinal Neurosurgery
Miami Herald
3 days ago
- Miami Herald
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging
Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1's effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company focused on reversing biological aging and age-related diseases, today announced compelling new preclinical data showing that its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines obtained from the Progeria Research Foundation. Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), is an ultra-rare pediatric disorder caused by a mutation in the LMNA gene. This mutation results in the production of an abnormal protein called progerin, which drives rapid biological aging in children. There are an estimated 400-500 known cases worldwide, including fewer than 30 children currently living with the disease in the United States. Symptoms typically begin within the first two years of life and include growth failure, joint stiffness, loss of body fat and hair, and severe cardiovascular disease. Children with progeria have an average life expectancy of just 13 to 15 years, with most dying from heart attacks or strokes at a young age. The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years. However, Zokinvy does not reverse the underlying disease pathology or halt cardiovascular deterioration, which remains the leading cause of death. No approved therapy restores normal cell function or reverses the biological hallmarks of accelerated aging in progeria, highlighting a significant and urgent unmet medical need. Telomir-1 is designed to regulate intracellular metal ions, reduce oxidative stress, restore mitochondrial function, extend telomere length, reverse muscle loss, and reset age-associated DNA methylation patterns - all of which are critical biological pathways implicated in progeria and broader age-related diseases. In this study, conducted by Smart Assays, Telomir-1 was tested in cells taken directly from a child with HGPS. These cells were obtained from The Progeria Research Foundation ( The study evaluated cell viability, reactive oxygen species (ROS), and intracellular calcium signaling - a marker of mitochondrial dysfunction - under both normal and stress-induced conditions. Key findings include: Improved cell viability: Telomir-1 increased survival in a dose-dependent manner, both under basal conditions and even under stress conditions induced by copper and iron-two metal ions known to accelerate aging by generating oxidative damage and destabilizing DNA and of oxidative stress: Progeria cells exhibited abnormally high levels of reactive oxygen species (ROS), a hallmark of cellular aging. Telomir-1 normalized these levels, both under basal conditions and even when ROS was further elevated by toxic metal of mitochondrial function: Iron-induced calcium overload - a signal of mitochondrial damage and a known feature of HGPS - was significantly reduced with Telomir-1, indicating restored mitochondrial regulation and improved cellular energy balance. These results demonstrate that Telomir-1 directly addresses the core cellular dysfunctions driving disease features in progeria - not only protecting cells from damage but restoring critical biological functions. The fact that these results were observed in actual patient-derived human cells offers strong early validation of Telomir-1's therapeutic potential. "These results provide the strongest evidence to date that Telomir-1 is not only protective but also restorative at the molecular and cellular level," said Dr. Angel, Chief Scientific Advisor of Telomir. "What's especially promising is that the improvements we observed directly target the mechanisms known to drive disease progression in progeria - oxidative stress, metal toxicity, and mitochondrial instability. This level of functional rescue in actual patient-derived cells is highly encouraging as we move toward clinical translation. These studies come as further validation of the very promising results obtained previously in both nematode and zebrafish models of adult progeria." "These findings deepen our conviction that Telomir-1 can be a first-in-class therapeutic platform for rare aging syndromes and broader age-related diseases," said Erez Aminov, CEO of Telomir. "By demonstrating the ability to reverse cellular damage in human progeria cells, Telomir-1 represents a potential breakthrough for children who currently have no real options beyond modestly delaying the inevitable. This work also lays the foundation for broader applications in neurodegeneration, metabolic dysfunction, and systemic aging. The new data also build on previously reported studies in zebrafish and C. elegans nematodes harboring the wrn gene mutation (a model of adult progeria, or Werner syndrome), where Telomir-1 significantly extended lifespan, restored telomere length, reversed muscle degeneration, and normalized molecular age markers. Telomir is currently finalizing IND-enabling studies for Telomir-1 and plans to engage with the U.S. Food and Drug Administration (FDA) to explore regulatory pathways, including the potential for orphan drug designation. The company is evaluating multiple rare disease indications for initial clinical development. Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moya info@ 396-6723 SOURCE: Telomir Pharmaceuticals, Inc
